1 / 55

Pain Assessment & Management

Pain Assessment & Management . M3 Palliative Medicine Curriculum Seema S. Limaye, MD University of Chicago. GOALS. Describe methods of pain assessment in cognitively impaired older adults. Understand various types of pain. Describe the basic pharmacology of opioids

daniel_millan
Download Presentation

Pain Assessment & Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pain Assessment & Management M3 Palliative Medicine Curriculum Seema S. Limaye, MD University of Chicago

  2. GOALS • Describe methods of pain assessment in cognitively impaired older adults. • Understand various types of pain. • Describe the basic pharmacology of opioids • Understand how to initiate and titrate opioids.

  3. Self-Directed Learning Modules • Basics of Neuropathic pain • Side Effects of Opiods and Management Options • Treatment of Pain in Persons with h/o Substance Abuse

  4. Mrs. P 70 y.o. female h/o Paget’s disease, renal insufficiency, osteoporosis presents to clinic with new back pain. What do you want to obtain from the history?

  5. Pain History • Pain Characteristics – onset, duration, location, quality, intensity, associated symptoms, exacerbating and relieving factors • Past and current management therapies • Relevant medical and family history • Psychosocial history • Impact of pain on daily life – work, daily activities, personal relationships, sleep, appetite, emotional state • Patient (and family’s) expected goals for treatment

  6. Pain: A Complex Phenomenon • Pain • Sensory stimuli and/or neurologic injury modified by an individual’s memory, expectations, emotions • Biocultural Model of Pain: • Society also influences an individual’s pain experiences

  7. Pain Assessment is NOT…. • Relying on changes in vital signs • Deciding a patient does not “look in pain” • Knowing how much a procedure or disease “should hurt” • Assuming a sleeping patient does not have pain • Assuming a patient will tell you they are in pain

  8. Consequences of Untreated Pain • Acute pain: • increase metabolic rate and blood clotting, • impair immune function • induce negative emotions • Without intervention, pain receptors become sensitive and may have long lasting changes in the neurons

  9. Consequences of Untreated Pain • Chronic pain may lead to: • fatigue, • anxiety, • depression, • confusion, • increased falls, • impaired sleep, and • decreased physical functioning/deconditioning

  10. Bedside Assessment • ASK the patient about pain • Asking about ADL’s and IADL’s • Asking about physical activity, mood, sleep, appetite, energy level • Identify preferred pain terminology -hurting, aching, stabbing, discomfort, soreness • Use a pain scale that works for the individual -Insure understanding of its use -Modify sensory deficits Ferrell et al. J Pain Symptom Manage 1995. Chinball and Tait Pain 2001. Herr and Garand. Pain Management in the Elderly 2001

  11. Use a standard scale to track the course of pain

  12. Faces Pain Scale and Pain Thermometer

  13. What are some common barriers to pain treatment?

  14. Remember the common patient-related barriers to pain management • Drugs .. • are addicting • should be saved for when it is really needed • have unpleasant or dangerous side effects • pills are not as effective as a shot • narcotics are only for dying people

  15. Pain assessment in a vulnerable group: Cognitively Impaired Older Adults

  16. Assessing pain: Nonverbal, Moderate to Severe Impairment • Formal assessment tools available but not necessarily useful in routine clinical settings • Unique Pain Signature • Nonverbal Pain Indicators Kaasalainen et al Perspectives 1998. Herr and Garand Clinics in Geriatric Medicine 2000

  17. Unique Pain Signature • How does the patient usually act? • What changes are seen when they are in pain? • family members • nursing staff • Communication across caregiver settings is key! Kovach et al. J Pain Symptom Manage 1999. Feldt et al. JAGS 1998. Weiner et al. Aging 1998.

  18. Nonverbal Pain Indicators • Facial expressions (grimacing) -Less obvious: slight frown, rapid blinking, sad/frightened, any distortion • Vocalizations (crying, moaning, groaning) -Less obvious: grunting, chanting, calling out, noisy breathing, asking for help • Body movements (guarding) -Less obvious: rigid, tense posture, fidgeting, pacing, rocking, limping, resistance to moving Kaasalainen et al Perspectives 1998. Herr and Garand Clinics in Geriatric Medicine 2000

  19. Selection of pain meds • Source/type of pain • Duration/timing/frequency • History of medication use • Impact on quality of life • Presence of associated factors

  20. Types of Pain: A Brief Review • Nociceptive Pain • Visceral • Somatic • Neuropathic Pain • Mixed/Unspecified Pain • Psychologic cause

  21. Quality: Visceral Pain • Descriptors: cramping, squeezing, pressure • Distribution/Examples: • Referred • heart attack, kidney stone • Colicky • Bowel obstruction, gallstone • Diffuse • Peritonitis • Analgesics: opioids; acetaminophen

  22. Quality: Somatic pain • Descriptors:aching, deep, dull, gnawing • Distribution/Examples: • Well localized—patients can often point with one finger to the location of their pain • bone mets, strained ankle, toothache • Analgesics:NSAIDS, acetaminophen opioids

  23. General Principles of Management • Set a goal of reduction of pain to tolerable levels, not a goal of complete relief • “Start low and go slow” • Make sure patient and family are aware of goals • Frequent clinic visits at first for assurance, validation, and monitoring of titration

  24. WHO 3-Step ladder Source: World Health Organization. Technical Report Series No. 804, Figure 2. Geneva: World Health Organization; 1990. Reprinted with permission.

  25. Non-opioid medications • Acetominophen 650mg tid-qid : concern for hepatic toxicity >3-4grams • NSAIDs including Ibuprofen, Naproxen, COX-2 inhibitors: concern for gastric / renal toxicity, platelet dysfunction, may inhibit anti-hypertensive meds

  26. Opioid combination products • The following opioids are available as combination products with acetaminophen, aspirin, or ibuprofen • Codeine; hydrocodone; oxycodone; propoxyphene • Typically used for • Moderate episodic (PRN) pain • Breakthrough pain in addition to a long-acting opioid. • Never prescribe more than one combination drug at any one time.

  27. Which combination product? Analgesic potency: • hydrocodone and oxycodone are more potent than codeine, which is more potent than propoxyphene, which some studies suggest is equipotent to aspirin. • there is little difference between hydrocodone products and oxycodone products in terms of potency. Note: propoxyphene products are not recommended for pain in most national pain guidelines, due to side effects and unclear efficacy compared to other products

  28. Adjuvants • Non-pharmacologic • Topicals • Tylenol • NSAIDS, Celecoxib, steroids • Anticonvulsants • Antidepressants • Antiarrhythmics

  29. Opioid Pharmacology • Block the release of neurotransmitters in the spinal cord • Agonist of Mu, delta, kappa receptors • Conjugated in liver • Excreted via kidney (90%–95%)

  30. Opioid pharmacology • Central and peripheral effects of opioids • This leads to desired effects, as well as side effects

  31. Clearance concerns • Conjugated by liver • 90%–95% excreted in urine • Dehydration, renal failure, severe hepatic failure •  dosing interval (extend time) or •  dosage size • if oliguria or anuria • STOP routine dosing of morphine • use ONLY prn

  32. Opiod Pharmacology… • What is the peak effect (C max ) of morphine: • PO? • 30-60 min • IV? • 5-15 min • SC/IM? • Variable…usually 30-60 min • What is the duration of effect of morphine? • PO? • 3-4 hours • IV? • Usually 1-2 hours, but we typically dose it q2-3 hours

  33. IV SC / IM Cmax po / pr Plasma Concentration 0 Time Half-life (t1/2)

  34. . . . More Opioid Pharmacology • Steady state after 4–5 half-lives • steady state after 1 day (24 hours) • Side Effects: • sedation, confusion, respiratory depression, constipation, urinary retention, nausea and vomiting

  35. Parenteral or Oral morphine hydromorphone (Dilaudid ®) meperidine (Demerol ®) codeine Oral only oxycodone (Percocet ® , Tylox ® ) hydrocodone (Vicodin ® Lortab ®, Lorcet ®) propoxyphene (Darvon ®, Wygesic ®) Note: hydrocodone is only available as a combination product. Short Acting Opioids

  36. Routine oral dosingextended-release preparations • Improve compliance, adherence • Dose q 8, 12, or 24 h (product specific) • don’t crush or chew tablets • may flush time-release granules down feeding tubes • Adjust dose q 2–4 days (once steady state reached)

  37. Transdermal Fentanyl • Duration 24-72 hours • 12-24 hours to reach full analgesic effect • Not recommended as first-line in opiate naïve patients • Lipophilic • Simple Conversion rule: -1 mg po morphine = ½ mcg fentanyl -(60 mg morphine roughly 25 mcg patch)

  38. DOSE FINDING

  39. ADDING AN OPIOID To achieve quick pain relief: (LOAD) 1. Start low dose, short-acting 2. Dose q peak 3. Re-eval in 4 hrs. to figure out what dose is needed

  40. Breakthrough dosing • Use immediate-release opioids • 10% of 24-h dose (or 1/3 of one ER dose) • offer after Cmax reached • po / pr  q 1 h • SC, IM  q 30 min • IV  q 10–15 min • Do NOT use extended-release opioids for breakthrough

  41. Ongoing assessment • Increase analgesics until pain relieved or adverse effects unacceptable • Be prepared for sudden changes in pain • plan for breakthroughs (prior to dressing changes or patient care activities)

  42. Opioid Dose Escalation Always increase by a percentage of the present dose based upon patient’s pain rating and current assessment 50-100% increase Severe pain 7-10/10 25-50% increase Moderate pain 4-6/10 25% increase Mild pain 1-3/10

  43. Incomplete cross-tolerance • If a switch is being made from one opioid to another it is recommended to start the new opioid at ~50% of the equianalgesic dose. • This is because the tolerance a patient has towards one opioid, may not completely transfer (“incomplete cross-tolerance”) to the new opioid. to 50% of new Opioid from 100%

  44. Pain Problem #1 • You started Mrs. T on 10 mg morphine every 4hrs around the clock for her cancer pain with good effect. She says she’s tired of taking a pill every 4 hours. Convert her to long-acting morphine with appropriate prn doses.

  45. Pain Problem #1: Answer • 24 hour use: 10mg PO morphine x 6 = 60 mg PO morphine • Convert to long-acting twice a day dosing: 60 mg PO morphine / 2 = 30mg PO morphine SR BID • Calculate prn dosing of morphine sulfate-immediate release: 60mg PO morphine in 24 h x 10% = 6mg PO morphine q3h prn breakthrough pain

  46. Part 2 • She is admitted to the hospital and unable to take oral medications--convert Mrs. T to: IV morphine

More Related